Abbott FreeStyle Libre System 2 Plus
DeviceThe sensor is placed subcutaneously at the back of the participant's upper arm with one insertion and measures the subcutaneous glucose concentration.
NCT Number: NCT06473480
This clinical trial aims to compare a continuous glucose monitoring system with traditional fingerstick blood glucose monitoring. The study focuses on adult patients in general surgical wards who need regular blood glucose checks due to the risk of low or high blood sugar levels.
The goal is to learn if using a continuous glucose monitoring system is better than fingerstick monitoring in managing glucose levels, preventing complications, improving patient satisfaction and experience, reducing nursing staff workload, and improving nursing staff' experience. The study also compares the accuracy of glucose readings from the continuous glucose monitoring system with those from fingerstick tests and blood samples.
The hypothesis is that CGMS is accurate and effective for monitoring glucose levels in surgical patients. This could lead to better blood sugar control, fewer complications, shorter hospital stays, and improved experiences for both patients and nursing staff.
Interested in participating?
Request Info18 year–110 year
All sexes
Interventional
Not applicable
Department of Surgery, Zealand University Hospital, Køge, Denmark
Glucose control in surgical patients at risk of hyperglycemia and hypoglycemia is essential, as these conditions can lead to infections, poor surgical outcomes, prolonged hospital stays, and death. In 2022, the prevalence of diagnosed diabetes in Denmark was 6.2%. With the global incidence of diabetes on the rise, the number of patients requiring glucose control during surgical admissions is increasing.
Point-of-care (POC) fingerstick capillary glucose monitoring (FSGM) is standard in many hospitals; however, FSGM can be painful, disrupt sleep, and increase postoperative stress for patients. Additionally, it can be time-consuming, requiring up to two hours of nursing work per patient daily. This makes timely and prescribed glucose monitoring challenging in busy surgical wards, potentially leading to untreated hyperglycemia and hypoglycemia. Moreover, FSGM provides only a snapshot of glucose levels, without indicating whether glucose is stable, rising, or falling.
An alternative to FSGM is continuous glucose monitoring systems (CGMS), which measure glucose levels via a subcutaneous sensor every few minutes. CGMS is predominantly used in ambulatory settings and has been shown to improve glucose regulation. Several studies have confirmed the accuracy of CGMS compared to FSGM in surgical and medical wards, reporting an overall mean absolute relative difference ranging from 9.4 to 12.9, making it acceptable for use in surgical wards. Other studies have reported that CGMS in surgical and medical wards results in superior glycemic control, reduced hypoglycemia, insulin usage, and in-hospital complications, and detected significant duration of both hypo- and hyperglycemia despite protocolized perioperative diabetes management compared to FSGM.
Studies on patients' perspectives of CGMS have been limited to everyday life and outpatient settings. One review on patients with type 1 and 2 diabetes experienced improved convenience, control, and freedom by the use of CGMS but were also overwhelmed by data and frustrated by inaccuracy, and technical issues, which is consistent with findings from another review of patients with diabetes type 2. Another study reported that patients with type 2 diabetes found the technology helpful for disease management, although it could also serve as an unpleasant reminder of disease progression and cause discomfort.
One case report has described nurses' experiences with CGMS in hospital wards for patients with type 1 diabetes. The nurses experienced an increased workload due to difficulties hearing the device receiver, leading to more frequent patient observations.
In summary, CGMS has been reported to be safe and beneficial in ambulatory settings, while challenges and knowledge gaps remain in hospital wards. To date, no studies have compared glucose levels from CGMS with those from a laboratory plasma glucose analyzer as the reference. This study aims to investigate the effect of CGMS compared to FSGM in patients with hyperglycemia in general surgical wards on glucose levels, complications, length of hospital stay, and patient satisfaction and experience with glucose management during hospitalization and up to three months after discharge. Additionally, the study will investigate the nursing staff's workload and experience in the surgical ward, and the accuracy of CGMS throughout hospitalization, including during surgical procedures and medical imaging.
Seven substudies will be conducted:
Substudy 1 - Glucose levels and management for surgical patients in relation to hospitalization: Compares point-of-care glucose levels and management using point-of-care FSGM and point-of-care CGMS during hospitalization and FSGM and continuous glucose monitoring (CGM) up to three months after discharge.
Substudy 2 - Patient satisfaction with glucose monitoring and management in surgical wards: Compares patient satisfaction with glucose monitoring and management for surgical patients using point-of-care FSGM and point-of-care CGMS during hospitalization.
Substudy 3 - Nursing staff's glucose monitoring and management workload in the surgical ward: Compares the nursing staff's workload with point-of-care FSGM to point-of-care CGMS for surgical patients.
Substudy 4 (qualitative study) - Patient experience of glucose monitoring and management in relation to hospitalization in surgical wards: Compares the patient experience with point-of-care FSGM to point-of-care CGMS and glucose management during hospitalization in the surgical ward and one compares the patient experience of FSGM with CGM one month after discharge.
Substudy 5 - Continuous glucose level for surgical patients in relation to hospitalization in the surgical ward: Compares the continuous glucose levels when glucose monitoring and management are performed by point-of-care FSGM and point-of-care CGMS in the surgical ward. Further, it compares continuous glucose levels using point-of-care FSGM and CGM after discharge.
Substudy 6 - Accuracy of CGMS for surgical patients during hospitalization: Investigates the accuracy of CGMS by comparing CGMS data with FSGM and plasma glucose data.
Substudy 7 (qualitative study) - Nursing staff's experience with fingerstick monitoring and CGSM for surgical patients: Compares the nursing staff's experience with point-of-care FSGM to point-of-care CGMS and glucose management for surgical patients.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Eligibility criteria solely for substudy 7
Inclusion criteria
The sensor is placed subcutaneously at the back of the participant's upper arm with one insertion and measures the subcutaneous glucose concentration.
The sensor is placed subcutaneously at the back of the participant's upper arm with one insertion and measures the subcutaneous glucose concentration.
Time frame: During hospitalization (up to 30 days)
Point-of-care glucose levels measured by point-of-care continuous glucose monitoring system (CGMS) or point-of-care fingerstick capillary glucose monitoring (FSGM)
Arm allocation:
Period 1: FSGM Period 2: CGMS Number of measurements: minimum four times daily, hourly if fasting. Blood glucose measurement: mmol/L
Time frame: During hospitalization (up to 30 days)
Using the validated Danish version of the 22-item questionnaire: The Diabetes Treatment Satisfaction Questionnaire for Inpatients (DTSQ-IP), item 4: How convenient did you think the diabetes treatment was at hospitalization?
Ranging from 0 - 6
0 represents 'At no time' 6 represents 'At most of the time'
Time frame: During hospitalization (up to 30 days)
Mean time: minutes.
Data include:
Time frame: During hospitalization (up to 30 days)
Percentage of time in range (3.9-10.0 mmol/l) during the entire hospital stay
Time frame: During hospitalization (up to 30 days)
Glucose levels from CGMS are compared to plasma glucose, which are co-analyzed in blood tests.
Time frame: During hospitalization (up to 30 days)
Unit: International units (IE)
Time frame: During hospitalization (up to 30 days)
Unit: International units (IE)
Time frame: During hospitalization (up to 30 days)
Estimated Glomerular Filtration Rate
Time frame: During hospitalization (up to 30 days)
Defined as suspected or confirmed infection, as well as organ damage
Time frame: During hospitalization (up to 30 days)
Plasma creatinine, μmol/L
Time frame: During hospitalization (up to 30 days)
The date for the first acute transfer to the intensive care unit and back to the surgical ward The number of days at the intensive care unit
Unit: Days
Time frame: During hospitalization (up to 30 days)
The date for the second acute transfer to the intensive care unit and back to the surgical ward The number of days at the intensive care unit
Unit: Days
Time frame: During hospitalization (up to 30 days)
CRP, leucocytes, central body temperature. Unit: Days
Time frame: During hospitalization (up to 30 days)
Received antibiotics Unit: Days
Time frame: During hospitalization (up to 30 days)
Presence of bedsore during hospitalization: yes/no
Time frame: During hospitalization (up to 30 days)
Diabetes ketoacidosis, defined as: pH < 7.30 and blood ketones > 3 mmol/L. Unit: Number of occurrence.
Time frame: During hospitalization (up to 30 days)
Presence of anastomotic leak during hospitalization: yes/no
Time frame: 30-days after discharge from hospital
Assesment of 30-day numbers of readmissions
Time frame: During hospitalization (up to 30 days)
Yes or no
Time frame: 90-days after discharge from hospital
Assesment of 90-day numbers of mortality.
Time frame: 90-days after discharge from hospital
mmol/mol
Time frame: 90-days after discharge from hospital
Percentage
Time frame: During hospitalization (up to 30 days)
Ranging from 0 - 6
0 represents 'At no time' 6 represents 'Very satisfied'
Time frame: During hospitalization (up to 30 days)
Ranging from 0 - 6
0 represents 'At no time' 6 represents 'At most of the time'
Time frame: During hospitalization (up to 30 days)
Ranging from 0 - 6
0 represents 'very unsatisfied"/"very inflexible' 6 represents ''very satisfied"very flexible"
Time frame: During hospitalization (up to 30 days)
Ranging from 0 - 6
0 represents 'very unsatisfied' 6 represents 'very satisfied'
Time frame: During hospitalization (up to 30 days)
Ranging from 0 - 6
0 represents 'very unsatisfied' 6 represents 'very satisfied'
Time frame: During hospitalization (up to 30 days)
Measurement: Mean minutes
Time frame: During hospitalization (up to 30 days)
The mean minutes diabetes nurses spent collecting information about glucose levels and management, supervising patients and surgical professionals, and being supervised by endocrinologists.
Time frame: During hospitalization (up to 30 days)
Percentage of time above range (TAR) 10,1-13.9 mmol/l
Time frame: During hospitalization (up to 30 days)
Percentage of time above range >13.9 mmol/l
Time frame: During hospitalization (up to 30 days)
Percentage of time below range 3.0-3.9 mmol/l
Time frame: During hospitalization (up to 30 days)
Percentage of time below range <3.0 mmol/l
Time frame: During hospitalization (up to 30 days)
mmol/l
Time frame: During hospitalization (up to 30 days)
SD divided by mean glucose level
Time frame: During hospitalization (up to 30 days)
mmol/l
Time frame: During hospitalization (up to 30 days)
mmol/l
Time frame: During hospitalization (up to 30 days)
Duration more than 15 consecutive minutes
Time frame: During hospitalization (up to 30 days)
Duration more than 15 consecutive minutes
Time frame: During hospitalization (up to 30 days)
Number
Time frame: During hospitalization (up to 30 days)
Glucose levels from CGMS are compared to FSGM data, which are co-analyzed in blood tests.
Contact information is provided by the study sponsor or research team.
Odense University Hospital
Other
Continuous GLUCOse Monitoring System With a SENSor Compared to Fingerstick Glucose Monitoring in Surgical Wards (GLUCOSENS)
Acronym: GLUCOSENS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05442853
Critical Illness, Diabetes Mellitus
Gainesville, Florida, United States
View Trial DetailsNCT06694012
Arterial Occlusive Diseases, Arteriosclerosis
Sakai, Osaka, Japan
View Trial DetailsNCT07502690
Diabetes Mellitus, Endocrine System Diseases
Jakarta, Jakarta Special Capital Region, Indonesia
View Trial DetailsNCT04662879
Body Weight, Body Weight Changes
Pasadena, California, United States
View Trial Details